MedTrace Logo

Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus

NCT02539459 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-12-15

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to see if oral everolimus is tolerable and effective in the treatment of sporadic Angiomyolipomas (AMLs). AMLs are the most common non-cancerous tumor of the kidney. They are composed of blood vessels, muscle cells and fat cells.Everolimus is already an approved drug for several other diseases like kidney cancer, but is being studied now specifically to see if it is helpful for people with AML.

Conditions

  • Sporadic Angiomyolipomas (AMLs)

Interventions

DRUG

Everolimus

10 mg tablets

Sponsors & Collaborators

Principal Investigators

  • Robert G Uzzo, MD · PI

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-23
Primary Completion
2018-08-20
Completion
2018-08-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02539459 on ClinicalTrials.gov